Fleet Phospho-soda Information Center: __________________ Symptoms of Possible Kidney Problems Acute Phosphate Nephropathy Oral Sodium Phosphate can cause Acute Phosphate Nephropathy Visicol and OsmoPrep Phospho Soda Kidney Damage with Fleet Phospho-soda Renal Failure Caused by Oral Sodium Phosphate Solutions Justice for those Injured by OSP We will work under a Contingency Fee Contract

On December 11, 2008 the FDA announced that Oral Sodium Phosphate (OSP) products used for bowel cleansing prior to colonoscopy or other procedures may cause or lead to acute phosphate nephropathy. The FDA announcement stated that they became aware of reports of acute nephropathy, a type of acute injury, that was associated with the use of oral sodium phosphate products. The products include in the announcement where the prescription products, Visicol and OsmoPrep, and over-the-counter oral sodium phosphate products that can be used as a laxative such as Fleet Phospho-soda EZ-prep.

The statement of the FDA included a sentence that stated that "in some cases when used for bowel cleansing, these serious adverse events have occurred in patients without identifiable factors that would put them at risk for acute kidney injury."  

If you were perfectly healthy and had had no signs of kidney problems prior to their exposure to an OSP, then suffered an injury call our Law Firm.  It is possible that the victims of this condition never had a problem with their kidneys and do not have a family history of kidney disease.

Who is at risk?

If you or a loved one had a colonoscopy and has used an oral sodium phosphate product for bowel cleansing prior to the colonoscopy.  According to the FDA, "individuals with an increased risk of acute phosphate nephropathy following the use of oral sodium phosphate (OSP) products include those who are over the age of 55; who are hypovolemic or have decreased intravascular volume; who have baseline kidney disease, bowel obstruction, or active colitis; and who are using medications that affect renal perfusion or function (such as diuretics, angiotensin converting enzyme [ACE] inhibitors, angiotensin receptor blockers [ARBs], and possibly nonsteroidal anti-inflammatory drugs [NSAIDs])."

The FDA is now requiring the manufacturer of Visicol and OsmoPrep to add Boxed Warning to the labeling for these prescriptions.

On the same day as the FDA alert, Fleet Laboratories voluntarily recalled its over-the-counter Phospho-soda products. Fleet issued a statement that "the recall decision was made to address the FDA's determination that oral sodium phosphate solutions used for bowel preparation prior to medical procedures such as colonoscopy should be available by prescription, and consumers should not be using over the counter products for bowel cleansing."






























TRADEMARK NOTICE: Visicol, OsmoPrep, Fleet Phospho-Soda are trademarks of C.B. Fleet Corporation.

The Carabin & Shaw Law Firm, its' lawyers and this website is in no way affiliated with C.B. Fleet Corporation. The use of this mark is solely for informational and product identification purposes.